Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats severe hypoglycemia. Sold as Zegalogue. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Dasiglucagon hydrochloride (sold as Zegalogue), first approved Mar 22, 2021, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Zegalogue Autoinjector
Part D
$7.2M
39×
11,013
Zegalogue Syringe
Part D
$1.3M
152×
1,951
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Zegalogue
$1.8M for 3,698 prescriptions, +64% on 2024
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Zegalogue 0.6 mg/0.6 mL autoinj: $493.36 per mLBrand · 0% in a year
Zegalogue 0.6 mg/0.6 mL syring: $494.54 per mLBrand · 0% in a year
How its trials ended
18 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 8 whose ending is known, 75% met their primary endpoint, 0% missed it and 25% stopped early.
Completed, result not reported739%Completed, result not reportedCount7Share39%
Met its primary endpoint633%Met its primary endpointCount6Share33%
Ongoing317%OngoingCount3Share17%
Stopped: other or unclear211%Stopped: other or unclearCount2Share11%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA